Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management
Liver International · 2025-01 · 45 (1)
DOI: 10.1111/liv.16027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 16.07.2024. Verfasst von Anna-Elisabeth Minder und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetology, and Porphyria, Stadtspital Zürich Triemli, Zurich, Switzerland. Hauptthemen laut MEDLINE: Protoporphyria, Erythropoietic, Protoporphyrins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The erythropoietic protoporphyrias consist of three ultra‐rare genetic disorders of the erythroid heme biosynthesis, including erythropoietic protoporphyria (EPP1), X‐linked protoporphyria (XLEPP) and CLPX‐protoporphyria (EPP2), which all lead to the accumulation of protoporphyrin IX (PPIX) in erythrocytes. Affected patients usually present from early childhood with episodes of severe phototoxic pain in the skin exposed to visible light. The quantification of PPIX in erythrocytes with a metal‐free PPIX ≥3 times the upper limit of normal confirms the diagnosis. Protoporphyria‐related complications include liver failure, gallstones, mild anaemia and vitamin D deficiency with reduced bone mineral density. The management is focused on preventing phototoxic reactions and treating the complications. Vitamin D should be supplemented, and DEXA scans in adults should be considered. In EPP1, even in cases of biochemically determined iron deficiency, supplementation of iron may stimulate PPIX production, resulting in an increase in photosensitivity and the risk of cholestatic liver disease. However, for patients with XLEPP, iron supplementation can reduce PPIX levels, phototoxicity and liver damage. Because of its rarity, there is little data on the management of EPP‐related liver disease. As a first measure, any hepatotoxins should be eliminated. Depending on the severity of the liver disease, phlebotomies, exchange transfusions and ultimately liver transplantation with subsequent haematopoietic stem cell transplantation (HSCT) are therapeutic options, whereby multidisciplinary management including porphyria experts is mandatory. Afamelanotide, an alpha‐melanocyte‐stimulating hormone analogue, is currently the only approved specific treatment that increases pain‐free sunlight exposure and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetology, and Porphyria, Stadtspital Zürich Triemli, Zurich, Switzerland.
- Swiss Reference Centre for Porphyrias, Stadtspital Zürich Triemli, Zurich, Switzerland.
- Department of Internal Medicine, Porphyria Center Rotterdam, Center for Lysosomal and Metabolic Disease, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
- Institute of Laboratory Medicine, Stadtspital Zürich Triemli, Zurich, Switzerland.
- University of Zurich, Zurich, Switzerland.
ORCID-Profile: Anna-Elisabeth Minder, Louisa G Kluijver, Jasmin Barman-Aksözen, Elisabeth I Minder, Janneke G Langendonk
Zitieren
APA
Minder, A. E., Kluijver, L. G., Barman-Aksözen, J., Minder, E. I., & Langendonk, J. G. (2025). Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management. Liver International, 45(1). https://doi.org/10.1111/liv.16027
Vancouver
Minder AE, Kluijver LG, Barman-Aksözen J, Minder EI, Langendonk JG. Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management. Liver International. 2025;45(1). doi:10.1111/liv.16027
BibTeX
@article{Minder2025,
author = {Minder, Anna-Elisabeth and Kluijver, Louisa G and Barman-Aksözen, Jasmin and Minder, Elisabeth I and Langendonk, Janneke G},
title = {Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management},
journal = {Liver International},
year = {2025},
volume = {45},
number = {1},
doi = {10.1111/liv.16027}
}
EUVIMED